tradingkey.logo

Australia's Orthocell rises on strong June quarter revenue, upbeat US outlook

ReutersJul 1, 2025 4:00 AM

Orthocell shares OCC.AX rise 7.2% to A$1.260

Fourth top performer in ASX All Ordinaries Index .AORD

Regenerative medicine company reports June quarter revenue of A$2.73 mln ($1.79 mln), up 22.8% Q/Q and 48.4% Y/Y

Revenue driven by sales of flagship nerve repair product, Remplir, in Australia

U.S. sales of Remplir not included in June quarter revenue numbers; expects U.S. sales to ramp up during 1H26

($1 = 1.5225 Australian dollars)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI